Maze Therapeutics (MAZE) Revenue (2024 - 2026)
Maze Therapeutics (MAZE) reported Revenue of $20.0 million for Q1 2026, up 113.11% sequentially from -$152.5 million in Q4 2024.
Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of Revenue data on file, last reported at $20.0 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 114.81% YoY), and the FY2024 full-year result was $15.0 million, changed N/A from the prior year.
- Revenue improved to $20.0 million in Q1 2026, from -$152.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $20.0 million in Q1 2026 to a low of -$152.5 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | 20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2024 | -152.50 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 15.00 Mn |